Niacin extended-release: Niaspan

CSR Synopses following approval of a new medicine or a new indication for an approved medicine in the US or EU. We are making CSR synopses available to supplement the public information available to patients and healthcare providers about the results of our clinical trials and the evidence used to approve a new medicine or a new indication.

{m} Entries

Phase
Study Indication or Disease
Study Name
M10-229 AbbVie_IU_icons_outlined_v3 N A Phase 3 A Randomized, Double-Blind, Parallel, Multicenter Placebo-Controlled Prospective Study to Evaluate the Functionality of the Flushing Assessment Tool (FAST) in Subjects Administered Niaspan® Plus Acetylsalicylic Acid (ASA), Niaspan® Plus ASA Placebo or Niaspan® Placebo Plus ASA Placebo Daily for Six Weeks
M10-241 AbbVie_IU_icons_outlined_v3 N A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, One-week Run-In of Aspirin 325 mg or Aspirin Placebo Followed by AspiRIin 325 mg or Aspirin Placebo 30 Minutes Prior to or with Open-Label Niaspan ER (Niacin Extended-Release) to Evaluate the Effects of Aspirin on Flushing in Subjects with Dyslipidemia (ASPIRIN PRIMER-500)